Page last updated: 2024-12-06

pinaverium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pinaverium bromide is a synthetic anticholinergic drug that acts primarily by blocking the muscarinic receptors in the smooth muscle of the gastrointestinal tract. It is used to treat irritable bowel syndrome (IBS) with diarrhea, especially in patients with visceral hypersensitivity. Pinaverium's mechanism of action involves inhibiting the contraction of the intestinal smooth muscle, which reduces intestinal motility and relieves symptoms of abdominal pain, cramping, and diarrhea. The synthesis of pinaverium involves several steps, including the reaction of 2-bromo-1-phenyl-1-propanone with 4-amino-3-methoxybenzoic acid to form a key intermediate. This intermediate is then reacted with 1-(2-chloroethyl)-4-methylpiperazine to yield the final product. Pinaverium is studied because of its potential to provide symptomatic relief to patients with IBS, a common gastrointestinal disorder. '

pinaverium: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40704
CHEMBL ID1909324
CHEBI ID135811
SCHEMBL ID312166
MeSH IDM0060791

Synonyms (13)

Synonym
pinaverium
CHEBI:135811
bdbm50101975
59995-65-2
unii-u2368vve7o
SCHEMBL312166
CHEMBL1909324
DB09090
4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethyl-2-bicyclo[3.1.1]heptanyl)ethoxy]ethyl]morpholin-4-ium
Q1236146
4-(2-bromo-4,5-dimethoxybenzyl)-4-(2-(2-(6,6-dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy)ethyl)morpholin-4-ium
DTXSID90860655
4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-{2-[2-(6,6-dimethylbicyclo[3.1.1]heptan-2-yl)ethoxy]ethyl}morpholin-4-ium

Research Excerpts

Overview

Pinaverium bromide is a musculotropic spasmolytic agent. It acts by inhibiting transmembrane calcium movements, an effect similar to that of verapamil.

ExcerptReferenceRelevance
"Pinaverium bromide is a locally acting spasmolytic agent of the digestive tract. "( [The clinical pharmacological profile of pinaverium bromide].
Guslandi, M, 1994
)
2
"Pinaverium bromide is a specific calcium channel blocker used in the treatment of irritable bowel syndrome (IBS) for its spasmolytic activity. "( Effect of pinaverium bromide on jejunal motility and colonic transit time in healthy humans.
Barbier, JP; Bouchoucha, M; Cugnenc, PH; Fallet, M; Frileux, P; Salles, JP, 1992
)
2.13
"Pinaverium bromide is a musculotropic spasmolytic agent which acts by inhibiting transmembrane calcium movements, an effect similar to that of verapamil. "( Electrophysiological study of intravenous pinaverium bromide in cardiology.
Guerot, C; Khemache, A; Noel, B; Sebbah, J, 1988
)
1.98

Toxicity

ExcerptReferenceRelevance
" The other outcomes were the adverse events rate, HAMA/SAS score, and HAMD/SDS score."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.82
" Eleven RCTs reported adverse effects in both the PB plus FM and PB groups, there was no statistically significant difference in the adverse events rate between the 2 groups (n = 1207, OR = 2."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.82
"The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS-D, and it is safe for clinical use."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.82

Compound-Compound Interactions

ExcerptReferenceRelevance
"A systematic literature search was conducted in 7 databases covering the period up to July 2018 to identify randomized controlled trials (RCTs) of PB combined with FM versus PB alone for IBS-D."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.82
"The efficacy of PB combined with FM is superior to PB alone in the treatment of IBS-D, and it is safe for clinical use."( Efficacy and safety of pinaverium bromide combined with flupentixol-melitracen for diarrhea-type irritable bowel syndrome: A systematic review and meta-analysis.
Huang, L; Lv, X; Qin, J; Qin, L; Yang, Q, 2019
)
0.82

Bioavailability

ExcerptReferenceRelevance
" Thanks to their typical physico-chemical characteristics, they are poorly absorbed by the systemic circulation and generally remain in the gastrointestinal tract where they exert the muscle relaxant activity by a local activity."( Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome.
Evangelista, S, 2004
)
0.32
" Otilonium bromide is poorly absorbed from the GI tract, where it acts locally as an L-type calcium channel blocker, an antimuscarinic and a tachykinin NK2 receptor antagonist."( Role of antispasmodics in the treatment of irritable bowel syndrome.
Annaházi, A; Róka, R; Rosztóczy, A; Wittmann, T, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monoterpenoidAny terpenoid derived from a monoterpene. The term includes compounds in which the C10 skeleton of the parent monoterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)IC50 (µMol)1.75000.02201.64228.9000AID1207687
Voltage-dependent L-type calcium channel subunit alpha-1CRattus norvegicus (Norway rat)IC50 (µMol)1.75000.00132.24956.9000AID1207687
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)1.75000.00032.25459.6000AID1207687
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (20)

Processvia Protein(s)Taxonomy
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1207687Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (84)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (30.95)18.7374
1990's19 (22.62)18.2507
2000's12 (14.29)29.6817
2010's21 (25.00)24.3611
2020's6 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.83 (24.57)
Research Supply Index4.90 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index119.65 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (69.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials39 (41.49%)5.53%
Reviews6 (6.38%)6.00%
Case Studies7 (7.45%)4.05%
Observational2 (2.13%)0.25%
Other40 (42.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Trial of Pinverin (Pinaverium Bromide) to Reduce Bowel Uptake of FDG in a Variety of Cancer Patients Who Undergo FDG PET/CT [NCT02173964]Phase 458 participants (Actual)Interventional2014-07-31Completed
Application of Pinaverium Bromide in the Treatment of Patients With Post-cholecystectomy Sphincter of Oddi Dysfunction (SOD): A Randomized, Controlled and Multicenter Clinical Study [NCT02833103]Phase 4168 participants (Anticipated)Interventional2016-07-31Recruiting
A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome [NCT01641224]800 participants (Anticipated)Interventional2012-05-31Active, not recruiting
[NCT02882451]200 participants (Anticipated)Interventional2016-07-31Recruiting
A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome [NCT02330029]800 participants (Anticipated)Interventional2012-08-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]